<DOC>
	<DOCNO>NCT02593162</DOCNO>
	<brief_summary>Phase 2a study design assess safety , efficacy , pharmacokinetics Faldaprevir TD-6450 combination Ribavirin 12-week treatment duration treatment-naïve participant genotype 4 hepatitis C virus ( HCV ) infection .</brief_summary>
	<brief_title>A Study Faldaprevir , Ribavirin TD-6450 Participants With Genotype 4 Hepatitis C Virus Infection</brief_title>
	<detailed_description>A study evaluate safety effect treatment experimental antiviral drug combination ribavirin treatment-naïve participant genotype 4 hepatitis C infection . The study test safety effect alternative treatment 12 week . Secondary objective study determine pharmacokinetics study drug co-administered , evaluate HCV RNA kinetics treatment .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Chronic genotype 4 hepatitis C infection HCV RNA ≥ 10^4 IU/mL screen Hepatitis C virus treatment naive , define define never receive direct act antiviral ( DAA ) , receive ≤ 8 week interferon ≥ 6 month prior screen Absence cirrhosis define one following : A liver biopsy perform within 24 calendar month Day 1 show absence cirrhosis Transient elastography ( FibroScan® ) perform within 12 calendar month Day 1 result ≤ 12.5 kPa A FibroSure® score ≤ 0.48 AST : platelet ratio ( APRI ) ≤ 1 perform screen Infection hepatitis B virus ( HBV ) human immunodeficiency virus , HIV1 HIV2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>